Ontario, Canada (CU)_ Novartis Pharmaceuticals Canada Inc. is delighted to announce that it has entered into a multi-year collaboration agreement with Innodem Neurosciences to perform a ground-breaking clinical investigation to treat individuals affected with multiple sclerosis (MS). Patients with multiple sclerosis will be tested twice a month during the period of the clinical study, and the data will be compared by the physicians to spot even the small changes that demonstrate the disease progression which may not be visible in magnetic resonance imaging (MRI).
Novartis will support the clinical research with Innodem’s proprietary eye monitoring software technology powered by…
